The association said this measure, alongside the decision to keep the clawback tax at an unsustainable level, which actually destroy the local medicine industry and reduce patients’ access to affordable drugs, can have a catastrophic impact on Romanians’ health.
The association also warned that removing this type of medicines from the list of compensated drugs will affect people suffering from circulatory, digestive, neurological or rheumatic disorders, mostly the elderly.
It also said, citing data provided by CEGEDIM, a leading market research company for pharmaceutical industry, that eliminating this type of medicines from the list of compensated drugs would have a very low impact on the state budget, as they make up only nearly 11% of the value of amounts paid by the state on medicines in the first eight months of the year.
This type of medicines, however, accounted for 54% of total prescribed medicines used in Romania, which shows they are widely used, mainly by low-income people. (EUR1=RON4.5641)